EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pirfenidone use in fibrotic diseases: What do we know so far?

Aldo Torre iD, Froylan David Martínez-Sánchez iD, Sofía Mercedes Narvaez-Chávez iD, Mariana Ariel Herrera-Islas iD, Carlos Alberto Aguilar-Salinas iD, Jacqueline Córdova-Gallardo iD

Immunity, Inflammation and Disease · 2024-07 · 12 (7)

DOI: 10.1002/iid3.1335 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 05.07.2024. Verfasst von Aldo Torre und 5 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Unit, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubiran", Mexico City, Mexico. Hauptthemen laut MEDLINE: Pyridones, Fibrosis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pirfenidone has demonstrated significant anti‐inflammatory and antifibrotic effects in both animal models and some clinical trials. Its potential for antifibrotic activity positions it as a promising candidate for the treatment of various fibrotic diseases. Pirfenidone exerts several pleiotropic and anti‐inflammatory effects through different molecular pathways, attenuating multiple inflammatory processes, including the secretion of pro‐inflammatory cytokines, apoptosis, and fibroblast activation.

Objective

To present the current evidence of pirfenidone's effects on several fibrotic diseases, with a focus on its potential as a therapeutic option for managing chronic fibrotic conditions.

Findings

Pirfenidone has been extensively studied for idiopathic pulmonary fibrosis, showing a favorable impact and forming part of the current treatment regimen for this disease. Additionally, pirfenidone appears to have beneficial effects on similar fibrotic diseases such as interstitial lung disease, myocardial fibrosis, glomerulopathies, aberrant skin scarring, chronic liver disease, and other fibrotic disorders.

Conclusion

Given the increasing incidence of chronic fibrotic conditions, pirfenidone emerges as a potential therapeutic option for these patients. However, further clinical trials are necessary to confirm its therapeutic efficacy in various fibrotic diseases. This review aims to highlight the current evidence of pirfenidone's effects in multiple fibrotic conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesFibrosisHumansAnimalsAnti-Inflammatory Agents, Non-SteroidalIdiopathic Pulmonary FibrosisAntifibrotic Agents

Stichwörter der Autor:innen

Pirfenidonechronic liver diseasefibrosisinflammation

Substanzen

pirfenidonePyridonesAnti-Inflammatory Agents, Non-SteroidalAntifibrotic Agents

Autor:innen und Institutionen

  • Metabolic Unit, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubiran", Mexico City, Mexico.
  • Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.
  • Department of Internal Medicine, Hospital General "Dr. Manuel Gea González", Mexico City, Mexico.
  • Department of Hepatology, Hospital General "Dr. Manuel Gea González", Mexico City, Mexico.

ORCID-Profile: Aldo Torre, Froylan David Martínez-Sánchez, Sofía Mercedes Narvaez-Chávez, Mariana Ariel Herrera-Islas, Carlos Alberto Aguilar-Salinas, Jacqueline Córdova-Gallardo

Zitieren

APA

Torre, A., Martínez-Sánchez, F. D., Narvaez-Chávez, S. M., Herrera-Islas, M. A., Aguilar-Salinas, C. A., & Córdova-Gallardo, J. (2024). Pirfenidone use in fibrotic diseases: What do we know so far?. Immunity, Inflammation and Disease, 12(7). https://doi.org/10.1002/iid3.1335

Vancouver

Torre A, Martínez-Sánchez FD, Narvaez-Chávez SM, Herrera-Islas MA, Aguilar-Salinas CA, Córdova-Gallardo J. Pirfenidone use in fibrotic diseases: What do we know so far?. Immunity, Inflammation and Disease. 2024;12(7). doi:10.1002/iid3.1335

BibTeX
@article{Torre2024,
  author = {Torre, Aldo and Martínez-Sánchez, Froylan David and Narvaez-Chávez, Sofía Mercedes and Herrera-Islas, Mariana Ariel and Aguilar-Salinas, Carlos Alberto and Córdova-Gallardo, Jacqueline},
  title = {Pirfenidone use in fibrotic diseases: What do we know so far?},
  journal = {Immunity, Inflammation and Disease},
  year = {2024},
  volume = {12},
  number = {7},
  doi = {10.1002/iid3.1335}
}
Kostenlos starten →